| scholarly article | Q13442814 |
| P50 | author | Robert H. Purcell | Q2157414 |
| Harvey J. Alter | Q5677307 | ||
| P2093 | author name string | Shimizu YK | |
| Iwamoto A | |||
| Yoshikura H | |||
| Hijikata M | |||
| P2860 | cites work | Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus | Q27486056 |
| Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes | Q27486195 | ||
| Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections | Q29615900 | ||
| Nucleotide sequence and mutation rate of the H strain of hepatitis C virus | Q29619801 | ||
| Lack of Protective Immunity Against Reinfection with Hepatitis C Virus | Q29620909 | ||
| Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins | Q29620952 | ||
| Sequence analysis of the 5' noncoding region of hepatitis C virus | Q29620975 | ||
| Hypervariable regions in the putative glycoprotein of hepatitis C virus | Q33334316 | ||
| Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro | Q36390620 | ||
| Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line | Q37061606 | ||
| Characterization of hypervariable regions in the putative envelope protein of hepatitis C virus | Q42982262 | ||
| A long-term study of hepatitis C virus replication in non-A, non-B hepatitis | Q42984278 | ||
| Clinical significance of antibodies to nonstructural and core proteins of hepatitis C virus in posttransfusion hepatitis patients during long‐term follow‐up | Q43038799 | ||
| A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody. | Q43038977 | ||
| Thermostability of human immunodeficiency virus (HIV-1) in a liquid matrix is far higher than that of an ecotropic murine leukemia virus | Q45846803 | ||
| Non-A, non-B hepatitis in chimpanzees and marmosets | Q52850814 | ||
| Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis | Q72400334 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| Hepatitis C virus | Q708693 | ||
| antibody | Q79460 | ||
| hepatitis C | Q154869 | ||
| P304 | page(s) | 1494-1500 | |
| P577 | publication date | 1994-03-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses | |
| P478 | volume | 68 |
| Q64992876 | A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice. |
| Q30383939 | A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies |
| Q36065682 | A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses |
| Q27478295 | A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies |
| Q29615897 | A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells |
| Q43034517 | A reduction in selective immune pressure during the course of chronic hepatitis C correlates with diminished biochemical evidence of hepatic inflammation |
| Q40152553 | A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus |
| Q40487554 | Adaptability costs in immune escape variants of vesicular stomatitis virus |
| Q34048752 | Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus |
| Q38168827 | An insight into the diagnosis and pathogenesis of hepatitis C virus infection |
| Q43046620 | Analysis of hepatitis C viral quasispecies in liver transplantation |
| Q41047406 | Antibodies Directed to Envelope Proteins of Hepatitis C Virus Outside of Hypervariable Region 1 |
| Q39602767 | Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus |
| Q43035983 | Antibody responses against B‐cell epitopes of the hypervariable region 1 of hepatitis C virus in self‐limiting and chronic human hepatitis C followed‐up using consensus peptides |
| Q27473441 | Antigenic structure of the hepatitis C virus envelope 2 protein |
| Q27469889 | Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes |
| Q59351582 | Approaches, Progress, and Challenges to Hepatitis C Vaccine Development |
| Q42999204 | Assessment of genotype and molecular evolution of hepatitis C virus in formalin-fixed paraffin-embedded liver tissue from patients with chronic hepatitis C virus infection |
| Q41017108 | Attachment of hepatitis C virus to cultured cells: A novel predictive factor for successful interferon therapy |
| Q29048140 | Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. |
| Q33913588 | Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein |
| Q42988439 | Broadly reactive antibodies to hypervariable region 1 in hepatitis C virus-infected patient sera: Relation to viral loads and response to interferon |
| Q59349176 | Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? |
| Q41574270 | Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection |
| Q34296870 | Characterization of Anti-HCV Antibodies in IL-10-Treated Patients |
| Q42720978 | Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein |
| Q27469346 | Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli |
| Q33234572 | Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. |
| Q24514512 | Clinical significance of hepatitis C virus genotypes |
| Q45761050 | Comparative features of hepatitis C virus infection in humans and chimpanzees |
| Q36506935 | Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein |
| Q42986317 | Correlation between relative number of circulating low-density hepatitis C virus particles and disease activity in patients with chronic hepatitis C |
| Q38120201 | Current progress in development of hepatitis C virus vaccines |
| Q37365416 | Cytotoxic T cells and viral hepatitis |
| Q27480298 | DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid |
| Q56395915 | Defining Breadth of Hepatitis C Virus Neutralization |
| Q40866024 | Design and expression of fusion protein consists of HBsAg and Polyepitope of HCV as an HCV potential vaccine |
| Q47548062 | Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus |
| Q58700067 | Development and Characterization of Monoclonal Antibodies to the 32 kDa Viral Attachment Protein of Lymphocystis Disease Virus and Their Neutralizing Ability in Vitro |
| Q42985856 | Differences in Hypervariable Region 1 Quasispecies between Immune Complexed and Non-Immune Complexed Hepatitis C Virus Particles |
| Q42991400 | Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver |
| Q42981576 | Different hepatitis C virus dynamics of free-virions and immune-complexes after initiation of interferon-alpha in patients with chronic hepatitis C. |
| Q41488562 | Differentiation of acute from chronic hepatitis C virus infection by nonstructural 5B deep sequencing: a population-level tool for incidence estimation |
| Q45753905 | Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant fab fragments |
| Q27469661 | Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection. |
| Q42988433 | Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. |
| Q42982261 | Dynamics of viral quasispecies in hepatitis C virus infection |
| Q42986005 | Editorial: Interferon Therapy for Chronic HCV Hepatitis: Trick or Treat? |
| Q43041868 | Effect of antiviral treatment and host susceptibility on positive selection in hepatitis C virus (HCV). |
| Q34294938 | Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection |
| Q27469698 | Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. |
| Q27480822 | Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus |
| Q27469585 | Evolution of Hypervariable Region 1 of Hepatitis C Virus in Primary Infection |
| Q27469719 | Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy |
| Q27469638 | Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters |
| Q36290295 | Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1 |
| Q34262165 | Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex |
| Q42987908 | Floating density of hepatitis C virus particles and response to interferon treatment |
| Q27469675 | Generation and characterization of a hepatitis C virus NS3 protease-dependent bovine viral diarrhea virus |
| Q27472543 | Genetic Diversity and Tissue Compartmentalization of the Hepatitis C Virus Genome in Blood Mononuclear Cells, Liver, and Serum from Chronic Hepatitis C Patients |
| Q42991874 | Genetic evolution of the hypervariable region 1 in hepatitis C virus carriers with normal aminotransferase activities |
| Q27469620 | Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy |
| Q42991985 | Genetic heterogeneity of the hypervariable region I of Hepatitis C virus and lymphoproliferative disorders |
| Q36032051 | Glances in Immunology of HIV and HCV Infection |
| Q27478341 | HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release |
| Q64133328 | Hepatitis C |
| Q37967737 | Hepatitis C Virus Evasion Mechanisms from Neutralizing Antibodies |
| Q27485419 | Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses |
| Q34112888 | Hepatitis C virus (HCV) E1 and E2 protein regions that specifically bind to HepG2 cells |
| Q39755223 | Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions |
| Q32065399 | Hepatitis C virus core protein potentiates c-Jun N-terminal kinase activation through a signaling complex involving TRADD and TRAF2. |
| Q27486537 | Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C |
| Q41619963 | Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment |
| Q42982267 | Hepatitis C virus infection of a Vero cell clone displaying efficient virus-cell binding |
| Q36415637 | Hepatitis C virus infection of human hepatoma cell line 7721 in vitro. |
| Q35196430 | Hepatitis C virus infection: when silence is deception. |
| Q42988931 | Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice |
| Q38856649 | Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies |
| Q42996182 | Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate |
| Q42989367 | Hepatitis C virus-specific CTL responses in PBMC from chimpanzees with chronic hepatitis C: determination of CTL and CTL precursor frequencies using a recombinant canarypox virus (ALVAC) |
| Q34422738 | Hepatitis C virus. The importance of viral heterogeneity |
| Q41332828 | Hepatitis C virus: molecular biology and genetic variability |
| Q36642065 | Hepatitis C: progress and problems |
| Q71525038 | Hepatitis vaccines |
| Q41722708 | Hepatitis viruses: genetic variants and clinical significance |
| Q40937845 | Hepatocellular injury in hepatitis B and C virus infections. |
| Q27481224 | High levels of subgenomic HCV plasma RNA in immunosilent infections |
| Q40685050 | High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression |
| Q36666331 | Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection |
| Q27469599 | Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes |
| Q42996153 | Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity |
| Q28482261 | Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate |
| Q27469507 | Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection |
| Q57490859 | Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry |
| Q27469647 | Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees |
| Q27469334 | Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies. |
| Q27469524 | Immunity in Chimpanzees Chronically Infected with Hepatitis C Virus: Role of Minor Quasispecies in Reinfection |
| Q45750923 | Immunodominant B-cell domains of hepatitis C virus envelope proteins E1 and E2 identified during early and late time points of infection |
| Q29618957 | Immunology of hepatitis B virus and hepatitis C virus infection |
| Q34283828 | Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines |
| Q73260241 | Immunopathogenesis of hepatitis C virus infection |
| Q33809427 | Immunopathogenesis of hepatitis C virus infection |
| Q71752165 | Immunopathogenesis of viral hepatitis |
| Q34005309 | Immunopathogenesis of viral hepatitis |
| Q41574267 | Immunopathology of hepatitis C. |
| Q27331309 | Impaired antibody response causes persistence of prototypic T cell-contained virus |
| Q34422731 | In search of hepatitis C virus receptor(s) |
| Q27491029 | In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes |
| Q27487549 | In vitro selection of a neutralization-resistant hepatitis C virus escape mutant |
| Q34333821 | Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients |
| Q41173255 | Is there a role for immune responses in the pathogenesis of hepatitis C? |
| Q27485325 | Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus |
| Q34586396 | Isolation of Human Monoclonal Antibodies to the Envelope E2 Protein of Hepatitis C Virus and Their Characterization |
| Q45752127 | Limited humoral immunity in hepatitis C virus infection |
| Q27469567 | Long-Term Evolution of the Hypervariable Region of Hepatitis C Virus in a Common-Source-Infected Cohort |
| Q27469355 | Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus |
| Q37492623 | Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity |
| Q40839635 | Low cell binding ability of HCV is closely related to interferon treatment especially in patients with HCV genotype 2a/2b. A large series prospective study on Japanese patients with chronic hepatitis C. |
| Q27489056 | Low pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus Particles |
| Q35274913 | Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations |
| Q34788785 | Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins |
| Q27469459 | Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis |
| Q27478186 | Monitoring of Hepatitis C Virus Quasispecies in Chronic Infection by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Mutation Detection |
| Q27486010 | Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons |
| Q27488430 | Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity |
| Q28731355 | Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization |
| Q35242585 | Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance |
| Q40999449 | Neutralization of Different Geographic Strains of the Hepatitis E Virus with Anti-Hepatitis E Virus-Positive Serum Samples Obtained from Different Sources |
| Q35189019 | Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics |
| Q47939183 | Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection |
| Q34337134 | Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma |
| Q27027484 | Neutralizing antibody response to hepatitis C virus |
| Q34419527 | Neutralizing antiviral antibody responses |
| Q34047477 | Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423 |
| Q27469739 | Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets |
| Q30416187 | Occult infection with hepatitis C virus: friend or foe? |
| Q40334457 | Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors In Vitro and Ex Vivo |
| Q43035107 | Oral immunization with HCV-NS3—transformed Salmonella: Induction of HCV-specific CTL in a transgenic mouse model |
| Q41157475 | Pathogenesis of chronic hepatitis C and associated clinical manifestations |
| Q33870245 | Pathogenesis, diagnosis and management of hepatitis C. |
| Q40442669 | Pathology of hepatitis C virus infection |
| Q42993187 | Permissiveness of human biliary epithelial cells to infection by hepatitis C virus |
| Q34499902 | Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant |
| Q43035611 | Perspectives: towards a peptide-based vaccine against hepatitis C virus. |
| Q45547935 | Prevention of hepatitis C virus infection |
| Q29615898 | Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization |
| Q27487933 | Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein |
| Q27470002 | Production and Characterization of Monoclonal Antibodies Specific for a Conserved Epitope within Hepatitis C Virus Hypervariable Region 1 |
| Q37945171 | Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives |
| Q35022653 | Public versus personal serotypes of a viral quasispecies. |
| Q42992789 | Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood |
| Q33739366 | Quasispecies in viral persistence and pathogenesis of hepatitis C virus |
| Q33791250 | Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy |
| Q43040234 | Recombinant antibody Fab against the hypervariable region 1 of hepatitis C virus blocks the virus adsorption to susceptible cells in vitro |
| Q34594986 | Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization |
| Q30657711 | Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. |
| Q43034500 | Regulation of human hepatitis C virus replication by default RNA synthesis through transcription attenuation--a hypothesis |
| Q41669589 | Review: Hepatitis C virus, autoimmunity and rheumatic disease |
| Q43034928 | Selective transmission of hepatitis C virus in vivo and in vitro |
| Q27487004 | Separation of Hepatitis C genotype 4a into IgG-depleted and IgG-enriched fractions reveals a unique quasispecies profile |
| Q43036405 | Significance of IgG and IgM HCV antibody secretion in vitro in patients with chronic hepatitis C: correlation with disease activity and response to interferon-alpha |
| Q26774612 | Status of hepatitis C virus vaccination: Recent update |
| Q27470232 | Stealth and cunning: hepatitis B and hepatitis C viruses |
| Q33791664 | Strategies and prospects for vaccination against the hepatitis C viruses |
| Q40965203 | Susceptibility of human and non-human cell lines to HCV infection as determined by the centrifugation-facilitated method |
| Q41667276 | T cell mechanisms in the immunopathogenesis of viral hepatitis B and C |
| Q40983075 | TOFE human-B-cell-line-based adsorption-inhibition assay to detect HCV neutralizing antibodies |
| Q36671958 | The evolutionary epidemiology of vaccination |
| Q42981924 | The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage |
| Q34210660 | The molecular biology of hepatitis C virus. Genotypes and quasispecies |
| Q33596413 | The outcome of hepatitis C virus infection after liver transplantation--is it influenced by the type of immunosuppression? |
| Q38192357 | The past, present and future of neutralizing antibodies for hepatitis C virus |
| Q42979832 | The quantitative humoral immune response to the hepatitis C virus is correlated with disease activity and response to interferon-alpha |
| Q41574241 | The quasispecies of hepatitis C virus and the host immune response |
| Q44052146 | Time‐shift experiments and patterns of adaptation across time and space |
| Q27673453 | Toward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing Antibody |
| Q27470086 | Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1can induce antibodies cross-reacting with a large number of viral variants |
| Q41123041 | Ultrastructural observations of viral particles within hepatitis C virus-infected human B lymphoblastoid cell line. |
| Q42994469 | Unscrambling hepatitis C virus-host interactions |
| Q27477892 | Update on chronic viral hepatitis |
| Q43049593 | Vaccination against hepatitis C virus infection: miles to go before we sleep |
| Q35776114 | Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice. |
| Q36900143 | Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments |
| Q35960863 | Virology of hepatitis C virus |
| Q27469660 | Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3 |
Search more.